Ubs Group Ag Tiziana Life Sciences LTD Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TLSA
# of Institutions
32Shares Held
1.94MCall Options Held
19.2KPut Options Held
0-
Sanctuary Advisors, LLC Indianapolis, IN908KShares$844,0800.01% of portfolio
-
Geode Capital Management, LLC Boston, MA219KShares$203,3730.0% of portfolio
-
Hsbc Holdings PLC London, X0115KShares$107,2890.0% of portfolio
-
Morgan Stanley New York, NY110KShares$102,0640.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il104KShares$96,9900.0% of portfolio
About Tiziana Life Sciences Ltd
- Ticker TLSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,273,000
- Market Cap $95.1M
- Description
- Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...